Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules

Medicinal Research Reviews

Volumn 24, Issue 4, 2004, Pages 449-474

  Shih, Shin Ru ^a,d   Chen, Shu Jen ^b   Hakimelahi, Gholam Hossein ^b   Liu, Hsing Jang ^c   Tseng, Chen Tso ^b   Shia, Kak Shan ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b TaiGen Biotechnology   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

3C protease; Capsid protein VPI; Enterovirus; Picornavirus; Rhinovirus

Indexed keywords

3 METHOXY 6 [4 (3 METHYLPHENYL) 1 PIPERAZINYL]PYRIDAZINE; 3 METHYL 5 ETHYLRHODANINE; 4' ETHOXY 2' HYDROXY 4,6' DIMETHOXYCHALCONE; 4',6 DICHLOROFLAVAN; 5 (4' METHOXYBENZYLIDENE)RHODANINE; 5 [5 [2,6 DICHLORO 4 (4,5 DIHYDRO 2 OXAZOLYL)PHENOXY]PENTYL] 3 METHYLISOXAZOLE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BTA 188; CHALCONE DERIVATIVE; DISOXARIL; PIRODAVIR; PLECONARIL; PROTEIN VP1; PROTEINASE INHIBITOR; RHODANINE; RO 09 0696; RO 09 0881; SCH 38057; SCH 47802; SCH 48861; SCH 48972; SCH 48973; SCH 48974; SCH 49860; SDZ 35682; SDZ 880061; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; WIN 61605;

ANTIVIRAL ACTIVITY; COMMON COLD; COXSACKIE VIRUS A; COXSACKIE VIRUS B; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; ECHO VIRUS; ENTEROVIRUS; MOUSE; NONHUMAN; PICORNAVIRUS; POLIOMYELITIS VIRUS; REVIEW; RHINOVIRUS; SEROTYPE; VIROGENESIS; VIRUS ADSORPTION; VIRUS CAPSID; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CAPSID; ENTEROVIRUS; PROTEASE INHIBITORS; PROTEIN BINDING; RHINOVIRUS;

EID: 3042613589     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10067     Document Type: Review

References (133)

1. Melnick JL. Portraits of viruses: The picornaviruses. Intervirology 1983;20:61-100.
2. Sawyer MH. Enterovirus infections: Diagnosis and treatment. Curr Opin Pediatr 2001;13:65-69.
3. Rotbart HA, Hayden FG. Picornavirus infections: A primer for the practitioner. Arch Fam Med 2000; 9:913-920.
4. Oberste M, Schnurr D, Maher K, al Busaidy S, Pallansch M. Molecular identification of new picornaviruses and characterization of a proposed enterovirus 73 serotype. J Gen Virol 2001;82:409-416.
5. Coulepis AG, Locarnini SA, Westaway EG, Tannock GA, Gust ID. Biophysical and biochemical characterization of hepatitis V virus. Intervirology 1982;18:107-127.
6. Melnick JL. Classification of hepatitis A virus as enterovirus type 72 and of hepatitis B virus as hepadnavirus type 1. Intervirology 1982;18:105-106.
7. Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, Emini EA, Hanecak R, Lee JJ, van der WS, Anderson CW, Wimmer E. Primary structure, gene organization, and polypeptide expression of poliovirus RNA. Nature 1981;291:547-553.
8. Racaniello VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci USA 1981;78:4887-4891.
9. Callahan PL, Mizutani S, Colonno RJ. Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14. Proc Natl Acad Sci USA 1985;82:732-736.
10. Chua BH, McMinn PC, Lam SK, Chua KB. Comparison of the complete nucleotide sequences of echovirus 7 strain UMMC and the prototype (Wallace) strain demonstrates significant genetic drift over time. J Gen Virol 2001;82:2629-2639.
11. Kaku Y, Sarai A, Murakami Y. Genetic reclassification of porcine enteroviruses. J Gen Virol 2001;82:417-424.
12. Shih SR, Ho MS, Lin KH, Wu SL, Chen YT, Wu CN, Lin TY, Chang LY, Tsao KC, Ning HC, Chang PY, Jung SM, Hsueh C, Chang KS. Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot, and mouth disease during an epidemic in Taiwan, 1998. Virus Res 2000;68:127-136.
13. Lindberg AM, Johansson S, Andersson A. Echovirus 5: Infectious transcripts and complete nucleotide sequence from uncloned cDNA. Virus Res 1999;59:75-87.
14. Lyons T, Murray KE, Roberts AW, Barton DJ. Poliovirus 5′-terminal cloverleaf RNA is required in cis for VPg uridylation and the initiation of negative-strand RNA synthesis, J Virol 2001;75:10696-10708.
15. Zell R, Sidigi K, Bucci E, Stelzner A, Gorlach M, Determinants of the recognition of enteroviral cloverleaf RNA by coxsackievirus B3 proteinase 3C. RNA 2002;8:188-201.
16. Rivera VM, Welsh JD, Maizel JV, Jr. Comparative sequence analysis of the 5′ noncoding region of the enteroviruses and rhinoviruses. Virology 1988;165:42-50.
17. Skinner MA, Racaniello VR, Dunn G, Cooper J, Minor PD, Almond JW. New model for the secondary structure of the 5′ non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J Mol Biol 1989;207:379-392.
18. Back SH, Kim YK, Kim WJ, Cho S, Oh HR, Kim JE, Jang SK. Translation of polioviral mRNA is inhibited by cleavage of polypyrimidine tract-binding proteins executed by polioviral 3C(pro). J Virol 2002;76: 2529-2542.
19. Jacobson SJ, Konings DA, Sarnow P. Biochemical and genetic evidence for a pseudoknot structure at the 3′ terminus of the poliovirus RNA genome and its role in viral RNA amplification. J Virol 1993;67:2961-2971.
20. Caspar DL, Klug A. Physical principles in the construction of regular viruses. Cold Spring Harbor Symp Quant Biol 1962;27:1-22.
21. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985;317:145-153.
22. Chow M, Newman JF, Filman D, Hogle JM, Rowlands DJ, Brown F. Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature 1987;327:482-486.
23. Burke KL, Almond JW, Evans DJ. Antigen chimeras of poliovirus. Prog Med Virol 1991;38:56-68.
24. Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 1985;229:1358-1365.
25. Arnold E, Rossmann MG. Analysis of the structure of a common cold virus, human rhinovirus 14, refined at a resolution of 3.0 Å. J Mol Biol 1990;211:763-801.
26. Filman DJ, Syed R, Chow M, Macadam AJ, Minor PD, Hogle JM. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J 1989;8:1567-1579.
27. Krausslich HG, Wimmer E. Viral proteinases. Annu Rev Biochem 1988;57:701-754.
28. Lee CK, Wimmer E. Proteolytic processing of poliovirus polyprotein: Elimination of 2Apro-mediated, alternative cleavage of polypeptide 3CD by in vitro mutagenesis. Virology 1988;166:405-414.
29. Miyashita K, Okunishi J, Utsumi R, Tagiri S, Hotta K, Komano T, Tamura T, Satoh N. Cleavage specificity of coxsackievirus 3C proteinase for peptide substrate (2): Importance of the P2 and P4 residues. Biosci Biotechnol Biochem 1996;60:1528-1529.
30. Kemp G, Webster A, Russell WC. Proteolysis is a key process in virus replication. Essays Biochem 1992;27:1-16.
31. Etchison D, Milburn SC, Edery I, Sonenberg N, Hershey JW. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. J Biol Chem 1982;257:14806-14810.
32. Rose JK, Trachsel H, Leong K, Baltimore D. Inhibition of translation by poliovirus: Inactivation of a specific initiation factor. Proc Natl Acad Sci USA 1978;75:2732-2736.
33. Trachsel H, Sonenberg N, Shatkin AJ, Rose JK, Leong K, Bergmann JE, Gordon J, Baltimore D. Purification of a factor that restores translation of vesicular stomatitis virus mRNA in extracts from poliovirus-infected HeLa cells. Proc Natl Acad Sci USA 1980;77:770-774.
34. Gradi A, Svitkin YV, Imataka H, Sonenberg N. Proteolysis of human eukaryotic translation initiation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. Proc Natl Acad Sci USA 1998;95:11089-11094.
35. Svitkin YV, Gradi A, Imataka H, Morino S, Sonenberg N. Eukaryotic initiation factor 4GII (eIF4GII), but not eIF4GI, cleavage correlates with inhibition of host cell protein synthesis after human rhinovirus infection. J Virol 1999;73:3467-3472.
36. Feduchi E, Aldabe R, Novoa I, Carrasco L. Effects of poliovirus 2A(pro) on vaccinia virus gene expression. Eur J Biochem 1995;234:849-854.
37. Tolskaya EA, Romanova LI, Kolesnikova MS, Ivannikova TA, Smirnova EA, Raikhlin NT, Agol VI. Apoptosis-inducing and apoptosis-preventing functions of poliovirus. J Virol 1995;69:1181-1189.
38. Barco A, Feduchi E, Carrasco L. Poliovirus protease 3C(pro) kills cells by apoptosis. Virology 2000;266: 352-360.
39. Agol VI, Belov GA, Bienz K, Egger D, Kolesnikova MS, Raikhlin NT, Romanova LI, Smirnova EA, Tolskaya EA. Two types of death of poliovirus-infected cells: Caspase involvement in the apoptosis but not cytopathic effect. Virology 1998;252:343-353.
40. Kuo RL, Kung SH, Hsu YY, Liu WT. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J Gen Virol 2002;83:1367-1376.
41. Li ML, Hsu TA, Chen TC, Chang SC, Lee JC, Chen CC, Stollar V, Shih SR. The 3C protease activity of enterovirus 71 induces human neural cell apoptosis. Virology 2002;293:386-395.
42. Monto AS, Fendrick AM, Sarnes MW. Respiratory illness caused by picornavirus infection: A review of clinical outcomes. Clin Ther 2001;23:1615-1627.
43. Monto AS. Acute respiratory infection in children of developing countries: Challenge of the 1990s. Rev Infect Dis 1989;11:498-505.
44. Grist NR, Bell EJ, Assaad F. Enteroviruses in human disease. Prog Med Virol 1978;24:114-157.
45. Moore M. Centers for Disease Control. Enteroviral disease in the United States, 1970-1979. J Infect Dis 1982;146:103-108.
46. Cherry JD, Jahn CL. Herpangina: The etiologic spectrum. Pediatrics 1965;36:632-634.
47. Gilbert GL, Dickson KE, Waters MJ, Kennett ML, Land SA, Sneddon M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 1988;7:484-488.
48. Alexander JP, Jr., Baden L, Pallansch MA, Anderson LJ. Enterovirus 71 infections and neurologic disease-United States, 1977-1991. J Infect Dis 1994;169:905-908.
49. Landry ML, Fonseca SN, Cohen S, Bogue CW. Fatal enterovirus type 71 infection: Rapid detection and diagnostic pitfalls. Pediatr Infect Dis J 1995;14:1095-1100.
50. Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, Lim WL, Ong BB, Paul G, AbuBakar S, Lambert M. Fatal enterovirus 71 encephalomyelitis. J Pediatr 1998;133:795-798.
51. Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, Lee CY. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999;354:1682-1686.
52. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999;341:929-935.
53. Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S, Gacheva M, Mitov G, Ninov N, Tsylka E, Robinson I, Frolova M, Bashkirtsev V, Martiyanova L, Rodin V. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 1979;60:329-340.
54. Blomberg J, Lycke E, Ahlfors K, Johnsson T, Wolontis S, von Zeipel G. Letter: New enterovirus type associated with epidemic of aseptic meningitis and/or hand, foot, and mouth disease. Lancet 1974;2:112.
55. Chonmaitree T, Menegus MA, Schervish-Swierkosz EM, Schwalenstocker E. Enterovirus 71 infection: Report of an outbreak with two cases of paralysis and a review of the literature. Pediatrics 1981;67:489-493.
56. Kennett ML, Birch CJ, Lewis FA, Yung AP, Locarnini SA, Gust ID. Enterovirus type 71 infection in Melbourne. Bull World Health Organ 1974;51:609-615.
57. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus type 71 infections: Experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 1982;71: 217-227.
58. Samuda GM, Chang WK, Yeung CY, Tang PS. Monoplegia caused by Enterovirus 71: An outbreak in Hong Kong. Pediatr Infect Dis J 1987;6:206-208.
59. Hinson VK, Tyor WR. Update on viral encephalitis. Curr Opin Neurol 2001;14:369-374.
60. Rice SK, Heinl RE, Thornton LL, Opal SM. Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis. Clin Infect Dis 1995;20:931-937.
61. Center for Disease Control. 1991. Summary of notifiable diseases-United States. 40:771-773.
62. Parasuraman TV, Frenia K, Romero J. Enteroviral meningitis. Cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2001;19:3-12.
63. Kaplan MH, Klein SW, McPhee J, Harper RG. Group B coxsackievirus infections in infants younger than three months of age: A serious childhood illness. Rev Infect Dis 1983;5:1019-1032.
64. Abzug MJ, Levin MJ, Rotbart HA. Profile of enterovirus disease in the first two weeks of life. Pediatr Infect Dis J 1993;12:820-824.
65. Wang DM, Zhao GC, Zhuang SM, Zhang YC. An epidemic of encephalitis and meningoencephalitis in children caused by echovirus type 30 in Shanghai. Chin Med J 1993;106:767-769.
66. Weinstein L, Shelokov A, Seltser R. A comparison of the clinical features of poliomyelitis in adults and children. N Engl J Med 1952;246:296.
67. Auld PAM, Kevy SV, Eley RC. Poliomyelitis in children: Experience with 956 cases in the 1955 Massachusetts epidemic. N Engl J Med 1960;263:1093.
68. Martino TA, Liu P, Petric M, Sole MJ. Enteroviral myocarditis and dilated cardiomyopathy: A review of clinical and experimental studies. In: Rotbart HA, editor. Human enterovirus infections. Washington, DC: American Society of Microbiology; 1995. p 291.
69. Keeling PJ, Jeffery S, Caforio AL, Taylor R, Bottazzo GF, Davies MJ, McKenna WJ. Similar prevalence of enteroviral genome within the myocardium from patients with idiopathic dilated cardiomyopathy and controls by the polymerase chain reaction. Br Heart J 1992;68:554-559.
70. Liljeqvist JA, Bergstrom T, Holmstrom S, Samuelson A, Yousef GE, Waagstein F, Jeansson S. Failure to demonstrate enterovirus aetiology in Swedish patients with dilated cardiomyopathy. J Med Virol 1993; 39:6-10.
71. Uchio E, Yamazaki K, Ishikawa H, Matsunaga I, Asato Y, Aoki K, Ohno S. An epidemic of acute haemorrhagic conjunctivitis caused by enterovirus 70 in Okinawa, Japan, in 1994. Graefes Arch Clin Exp Ophthalmol 1999;237:568-572.
72. Maitreyi RS, Dar L, Muthukumar A, Vajpayee M, Xess I, Vajpayee RB, Seth P, Broor S. Acute hemorrhagic conjunctivitis due to enterovirus 70 in India. Emerg Infect Dis 1999;5:267-269.
73. Saitoh-Inagawa W, Aoki K, Uchio E, Itoh N, Ohno S. Ten years' surveillance of viral conjunctivitis in Sapporo, Japan. Graefes Arch Clin Exp Ophthalmol 1999;237:35-38.
74. Cherry JD. Enteroviruses: Polioviruses (poliomyelitis), coxackieviruses, echoviruses, and enteroviruses. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 3rd edition. Philadephia: WB Saunders; 1992. p 1705.
75. Otto MJ, Fox MP, Fancher MJ, Kuhrt MF, Diana GD, McKinlay MA. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother 1985;27:883-886.
76. Diana GD, McKinlay MA, Otto MJ, Akullian V, Oglesby CJ. [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. J Med Chem 1985;28:1906-1910.
77. Fox MP, Otto MJ, Shave WJ, McKinlay MA. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother 1986;30:110-116.
78. Diana GD, Otto MJ, Treasurywala AM, McKinlay MA, Oglesby RC, Maliski EG, Rossmann MG, Smith TJ. Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14. J Med Chem 1988;31:540-544.
79. Diana GD, Cutcliffe D, Oglesby RC, Otto MJ, Mallamo JP, Akullian V, McKinlay MA. Synthesis and structure-activity studies of some disubstituted phenylisoxazoles against human picornavirus. J Med Chem 1989;32:450-455.
80. Diana GD, Cutcliffe D, Volkots DL, Mallamo JP, Bailey TR, Vescio N, Oglesby RC, Nitz TJ, Wetzel J, Giranda V, Pevear DC, Dutko FJ. Antipicornavirus activity of tetrazole analogues related to disoxaril. J Med Chem 1993;36:3240-3250.
81. Diana GD, Volkots DL, Nitz TJ, Bailey TR, Long MA, Vescio N, Aldous S, Pevear DC, Dutko FJ. Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity. J Med Chem 1994;37:2421-2436.
82. Woods MG, Diana GD, Rogge MC, Otto MJ, Dutko FJ, McKinlay MA. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother 1989;33:2069-2074.
83. Bailey TR, Diana GD, Kowalczyk PJ, Akullian V, Eissenstat MA, Cutcliffe D, Mallamo JP, Carabateas PM, Pevear DC. Antirhinoviral activity of heterocyclic analogs of Win 54954. J Med Chem 1992;35:4628-4633.
84. Diana GD, Rudewicz P, Pevear DC, Nitz TJ, Aldous SC, Aldous DJ, Robinson DT, Draper T, Dutko FJ, Aldi C, Gendron G, Oglesby RC, Volkots DL, Reuman M, Bailey TR, Czerniak R, Block T. Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem 1995;38:1355-1371.
85. Weiner LB, Botbart HA, Gilbert DL, Hayden FG, Mynhardt JH, Dwyer DE, Trocha H, Rogers JM, McKinlay MA. 1997. Treatment of enterovirus meningitis with pleconaril (VP 63843), an antipicornaviral agent, abstr. LB-27, p 14. In: Program addendum of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
86. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999;43:2109-2115.
87. Watson KG, Wu WY, Krippner GY, McConnell DB, Jin B, Stanislawski PC, Brown RN, Chalmers DK, Tucker SP, Cameron-Smith R, Hamilton S, Luttick A, Ryan J, Reece PA. A new class of capsid-binder with potent inhibitory activity against rhinovirus in cell culture. Antiviral Res 2001;50:Abst. 126.
88. Hayden FG, Crump C, Reece PA, Watson K, Ryan J, Cameron-Smith R, Tucker SP. In vitro anti-rhinovirus spectrum and potency of BTA 188, a novel, oral picornavirus capsid binder. Antiviral Res 2001;50:Abst. 127.
89. Ryan J, Sidwell RW, Barnard D, Tucker SP, Reece PA. Preclinical pharmacokinetics of a new rhinovirus inhibitor, BTA 188. Antiviral Res 2001;50:Abst. 128.
90. Wu WY, Watson K, McConnell D, Jin B, Krippner G. 2000. Antiviral agents. World (PTC) Patent WO-0078746.
91. Watson K, Krippner G, Stanislawski P, McConnell D. 2002. Antiviral agents. World (PTC) Patent WO-0250045.
92. Krippner G, Reece PA, Watson KG, Wu WY, Jin B, Tucker SP. 2001. Antiviral agents. World (PTC) Patent WO-0119822.
93. Giranda VL. Structure-based drug design of antirhinoviral compounds. Structure 1994;2:695-698.
94. (a) Shia KS, Li WT, Chang CM, Hsu MC, Chern JH, Leong MK, Tseng SN, Lee CC, Lee YC, Chen SJ, Peng KC, Tseng HY, Chang YL, Tai CL, Shih SR. Design, synthesis, structure-activity relationship of pyridyl imidazolidinones: A novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem 2002;45:1644-1655.
95. (b) Shia KS, Shih SR, Chang CM, Chern JH, Li WT, Chen SJ, Hsu MC. 2003. Imidazolidinone compounds. US Patent US-0087936.
96. Rozhon E, Cox S, Buontempo P, O'Connell J, Slater W, DeMartino J, Schwartz J, Miller G, Arnold E, Zhang A, Morrow C, Jablonski S, Pinto P, Versace R, Duelfer T, Girijavallabhan V. SCH 38057: A picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res 1993;21:15-35.
97. Cox S, Buontempo PJ, Wright MJ, DeMartino JL, Skelton AM, Ferrari E, Schwartz J, Rozhon EJ, Linn CC, Girijavallabhan V, O'Connell JF. Antipicornavirus activity of SCH47802 and analogs: In vitro and in vivo studies. Antiviral Res 1996;32:71-79.
98. Buontempo PJ, Cox S, Wright MJ, DeMartino JL, Skelton AM, Ferrari E, Albin R, Rozhon EJ, Girijavallabhan V, Modlin JF, O'Connell JF. SCH 48973: A potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother 1997;41:1220-1225.
99. Al-Nakib W, Higgins PG, Barrow GI, Tyrrell DAJ, Andries K, Bussche GV, Taylor N, Janssen PAJ. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother 1989;33:522-525.
100. Chapman MS, Minor I, Rossmann MG. Human rhinovirus 14 complexed with antiviral compound R 61837. J Mol Biol 1991;217:455-463.
101. Hayden FG, Andries K, Janssen PAJ. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992;36:727-732.
102. Rosenwirth B, Kis ZL, Eggers HJ. In vivo efficacy of SDZ 35-682, a new picornavirus capsid-binding agent. Antiviral Res 1995;26:55-64.
103. Rosenwirth B, Oren DA, Arnold E, Kis ZL, Eggers HJ. SDZ 35-682, a picornavirus capsid-binding agent with potent antiviral activity. Antiviral Res 1995;26:65-82.
104. Oren DA, Zhang A, Nesvadba H, Rosenwirth B, Arnold E. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. J Mol Biol 1996;259:120-134.
105. Eggers HJ, Koch MA, Furst A, Daves GD, Jr., Wilczynski JJ, Folkers K. Rhodanine: A selective inhibitor of the multiplication of echovirus 12. Science 1970;167:294-297.
106. Eggers HJ. Selective inhibition of uncoating of echovirus 12 by Rhodanine. Virology 1977;78:241-252.
107. Bauer DJ, Selway JWT, Batchelor JF, Tisdale M, Caldwell IC, Young DAB. 4′,6-Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature 1981;292:369-370.
108. Genovese D, Conti C, Tomao P, Desideri N, Stein ML, Catone S, Fiore L. Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro. Antiviral Res 1995;27:123-136.
109. Prendergast PT. 2001. Use of flavones, coumarins, and related compounds to treat infections. World (PTC) Patent WO-0103681.
110. Conti C, Mastromarino P, Sgro R, Desideri N. Anti-picornavirus activity of synthetic flavon-3-yl esters. Antiviral Chem Chemother 1998;9:511-515.
111. Ishitsuka H, Ninomiya YT, Ohsawa C, Fujiu M, Suhara Y. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410. Antimicrob Agents Chemother 1982;22:617-621.
112. Ninomiya Y, Ohsawa C, Aoyama M, Umeda I, Suhara Y, Ishitsuka H. Antivirus agent, Ro 09-410, binds of rhinovirus specifically and stabilizes the virus conformation. Virology 1984;134:269-276.
113. Al-Nakib W, Tyrrell DAJ. A 'new' generation of more potent synthetic antirhinovirus compounds: Comparison of their MICs and their synergistic interactions. Antiviral Res 1987;8:179-188.
114. Abel MD, Cameron AD, Ha CM, Koski CA, Luu HT, Micetich RG, Nguyen DQ, Tempest ML, Daneshtalab M. Novel azolyalkyloxy compounds with antipicornaviral activity. Antiviral Chem Chemother 1995;6: 245-254.
115. Kenny MT, Dulworth JK, Bargar TM, Daniel JK. Antipicornavirus activity of some diaryl methanes and aralkylaminopyridines. Antiviral Res 1987;7:87-97.
116. Nobukatsu SN, Haruo KM, Masanobu AI. 1989. 2-(4-Pyridylaminomethyl)- benzimidazole derivatives having antiviral activity. US Patent US-4818761.
117. Straukas J, Dirvianskite N, Jankauskas R, Yavorovskaya VY, Yevstropov AN, Kiseleva VN. Synthesis and antiviral activity of N- and O-substituted amino acids. Khim Farm Zh 1996;30:18-21.
118. 1 glutamine isosteric replacements. J Med Chem 1998;41:2786-2805.
119. Dragovich PS, Zhou R, Webber SE, Prins TJ, Kwok AK, Okano K, Fuhrman SA, Zalman LS, Maldonado FC, Brown EL, Meador JW III, Patick AK, Ford CE, Brothers MA, Binford SL, Matthews DA, Ferre RA, Worland ST. Structure-based design of ketone-containing tripeptidyl human rhinovirus 3C protease inhibitors. Bioorg Med Chem Lett 2000;10:45-48.
120. Dragovich PS, Zhou R, Webber SE, Prins TJ, Reich SH, Kephart SE, Rui Y. 2001. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis. WO-0110894.
121. Xian M, Wang QM, Chen X, Wang K, Wang PG. S-Nitrosothiols as novel, reversible inhibitors of human rhinovirus 3C protease. Bioorg Med Chem Lett 2000;10:2097-2100.
122. (a) Dragovich PS, Webber SE, Prins TJ, Zhou R, Marakovits JT, Tikhe JG, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Brown EL, Binford SL, Meador JW III, Ferre RA, Worland ST. Structure-based design of irreversible tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids. Bioorg Med Chem Lett 1999;9:2189-2194 and references cited therein.
123. (b) Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 1999;96:11000-11007.
124. Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SR, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW III, Ferre RA, Brown EL, Binford SL, Harr JEV, DeLisle DM, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J Med Chem 1998;41:2819-2834.
125. (a) Tian Q, Nayyar NK, Babu S, Tao J, Moran TJ, Dagnino R, Jr., Mitchell LJ, Remarchuk TP. 2001. Synthetic route for the preparation of rhinovirus protease inhibitors and key intermediates. WO-0114329.
126. (b) Witherell G. AG-7088 Pfizer. Curr Opin Investig Drugs 2000;1:297-302.
127. Kaiser L, Crump CE, Hayden FG. In vitro activity of pleconaril and AC7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral res 2000;47:215-220.
128. Zalman LS, Brothers MA, Dragovitch PS, Zhou R, Prins TJ, Worland ST, Patrick AK. Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 2000;44:1236-1241.
129. Patrick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovitch PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999;45:2444-2450.
130. Reich SH, Kephart SE, Wallace MB, Hohnson TO, Jr. 2000. Substituted benzamide inhibitors of rhinovirus 3C protease. WO-0078708.
131. Webber SE, Tikhe J, Worland ST, Fuhrman SA, Hendrickson TF, Matthews DA, Love RA, Patick AK, Meador JW, Ferre RA, Brown EL, DeLisle DM, Ford CE, Binford SL. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J Med Chem 1996;39:5072-5082.
132. Arad D, Bollon AP, Young DG, Peek AS, Poland BW, Shaw B, Vallurupalli J. 2002. Cysteine protease inhibitors. Patent WO-02076939.
133. pro) structure: Basis for design of anti-SARS drugs. Science 2003;300:1763-1767.